drugset
drugset / Trial / NCT06222034

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

NCT06222034 ↗

Phase 1 Terminated 9 enrolled Alfasigma S.p.A.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).

Timeline

Start
2024-05-13
Primary completion
2026-06-17
Completion
2026-06-17

Outcome

Outcome not reported

Stopped (Enrollment): “The sponsor decided to stop recruitment and to early terminate the trial with 9 enrolled patients.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Filgotinib Small molecule — Oral

Indications

juvenile idiopathic arthritis